Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile

H.J. Jansen1*, G. Vervoort1, M. van der Graaf2, C.J. Tack1

Departments of 1Internal Medicine and 2Radiology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands, *corresponding author: tel.: +31 (0)24-361 38 89, fax: +31 (0)24-354 00 22, e-mail: H.Jansen@aig.umcn.nl

ABSTRACT

Pronounced weight gain after start of insulin therapy in patients with type 2 diabetes mellitus (T2DM) may offset beneficial effects conferred by the improvement of glycaemic control. This hypothesis was tested by comparing the cardiometabolic risk profile of a group of type 2 diabetes patients with a marked increase in body weight (‘gainers’) after the start of insulin treatment and a similar group without any or only minimal weight gain (‘non-gainers’). In a cross-sectional study, we compared two predefined groups of patients with T2DM who had been on insulin therapy for a mean of 4.0 years: ‘gainers’ vs ‘non-gainers’. Cardiometabolic risk was assessed by measuring fat content and distribution (physical examination, bioelectrical impedance analysis, dual energy X-ray absorption, and magnetic resonance imaging), liver fat content (magnetic resonance spectroscopy), physical activity levels (Sensewear® armband) and plasma markers.

Each subgroup consisted of 14 patients. Gainers had significantly more total body and trunk fat (especially subcutaneous fat) compared with non-gainers. Gainers had similar liver fat content, and slightly higher levels of fat hormones. Furthermore, gainers performed significantly less physical activity. Lastly, gainers had higher total cholesterol, low-density lipoprotein cholesterol, and alanine aminotransferase levels with similar cholesterol-lowering treatment.

Patients with T2DM who show pronounced weight gain during insulin therapy have a less favourable cardiometabolic risk profile compared with patients who show no or minimal weight gain.

KEYWORDS

Insulin-associated weight gain, type 2 diabetes mellitus, cardiometabolic risk profile

INTRODUCTION

Insulin therapy is frequently needed to achieve adequate glycaemic control in patients with type 2 diabetes mellitus (T2DM), but often at the expense of weight gain. Although values differ between studies, and studies are generally of limited duration, the estimated weight gain during the first year of insulin therapy ranges from approximately 2 to 6 kg. This weight gain shows large inter-individual differences, with some patients experiencing substantial insulin-associated weight gain, while others do not show any weight gain at all or even lose weight.

The determinants of insulin-associated weight gain are not entirely elucidated; most authors view the improvement in glycaemic control as the major determinant of weight gain. However, the level of improvement in glycaemic control is only weakly correlated with the increase in body weight. A frequently mentioned clinical experience is that a subset of patients exists that shows a persistent and continuous increase in body weight over time even when stable glycaemic control has been obtained.

It is obvious that weight gain in an already overweight population is undesirable. Weight gain will deter further optimisation of insulin therapy and in itself will adversely influence the cardiometabolic risk profile. Little is known about the effects of insulin-associated weight gain on cardiometabolic risk in patients with T2DM. One may hypothesise that the benefits of insulin treatment
in the ACCORD trial, the intensively treated group with T2DM showed increased mortality. In this group, more than 75% of the patients used insulin therapy in combination with several oral drugs. More than 25% of the patients treated in the intensive-therapy group showed a mean weight gain of >10 kg during follow-up. Although the study did not reveal any direct effect of the exaggerated weight gain on cardiovascular events, extensive weight gain might have had a negative influence on cardiometabolic risk.

In the present study, we hypothesised that pronounced weight gain during insulin therapy would be associated with an unfavourable cardiometabolic risk profile. This hypothesis was tested by comparing the cardiometabolic risk profile of insulin-treated patients with T2DM who showed weight gain at the extreme ends of the spectrum (‘gainers’ vs ‘non-gainers’).

RESEARCH DESIGN AND METHODS

Patient groups
Patients were selected out of a cohort of patients with T2DM who started insulin therapy in our University Diabetes Clinic between 2001 and 2006. To prevent confounding with respect to influences of different types of insulin on body weight we only included patients who started and continued on biphasic insulin (NovoMix® or Mixtard® insulin), twice-daily. Patients were selected based on the weight gain after starting insulin. We defined a ‘gainer’ as a patient who showed an increase in body weight of ≥0.5 kg/month within the first 18 months after starting insulin therapy and ≥5% weight gain at total follow-up (i.e. at the time of cross-sectional measurement, which was different for each patient). We defined a ‘non-gainer’ as a patient with a maximum weight gain ≤2.5 kg at follow-up. These criteria were derived from a historical insulin-treated group (n=140), and represent the upper and lower subgroups of weight gain. Assessment at follow-up of the cardiometabolic risk profile between the two groups (gainers vs non-gainers) was performed. All selected patients had a minimal follow-up of 18 months. Exclusion criteria were: heart failure (NYHA class III-IV), liver or renal disease (defined by chronic renal disease stage ≥III), hypoalbuminaemia, use of alcohol of more than 2 units/day, drug abuse, use of thiazolidinedione derivatives or prednisone, and pregnancy or the intention to become pregnant during the study. Eligible patients were not on anti-obesity medications and acarbose treatment. Also weight loss surgery patients or patients who followed any other weight management program were excluded.

The inclusion and exclusion criteria were reviewed at a screening visit, where patients underwent history taking and a complete physical examination. The study protocol was approved by the local ethics committee. All patients provided written informed consent.

Cardiometabolic risk assessment
Cardiometabolic risk profile at follow-up was assessed by the following: 1) body fat distribution (weight, height, waist and hip circumference, bioelectrical impedance analysis (BIA), dual energy X-ray absorption (DEXA), and MRI); 2) liver fat content (LFAT) by magnetic resonance spectroscopy (MRS); 3) physical activity levels; 4) classical risk factors, other biochemical cardiometabolic markers. Patients were tested after overnight fasting and with an empty bladder. To determine body mass index (BMI), weight (kg) was divided by height in metres, squared. Weight was measured with subjects wearing light underwear only. Scales were calibrated annually. Waist circumference was measured midway between the lower rib margin and the iliac crest at expiration, and hip circumference over the greater trochanter; waist-to-hip ratio (WHR) was calculated.

To assess fat distribution three different methods were used: BIA, DEXA and MRI. BIA was carried out using an Akern soft tissue analyser (BIA Quatum/S Body Composition Analyser model no. BIA-101, Akern Srl, Pontassieve (Florence), Italy). BIA was performed to assess total body water (TBWa) and fat-free mass (FFM). Patients rested in a supine position for approximately five minutes to equalise fluid compartments. Four surface electrodes were applied (two each to an arm and a leg). Phase sensitive sensors separated the components of the modulus into Reactance and Resistance.

Total-body DEXA scanning was performed using a Hologic QDR 4500 densitometer (Hologic Inc., Bedford, USA) to determine fat mass (total fat mass and trunk fat) and lean mass. To assess non-trunk fat, the trunk-to-leg ratio (trunk mass divided by leg mass) was calculated for each patient. MRI measurements were performed on a Tim-Trio MR system (Siemens, Erlangen, Germany). A series of T1-weighted (flash 2D) axial MR images was acquired from a region extending from 4 cm above to 4 cm below the fourth to fifth lumbar interspace. Visceral and subcutaneous fat areas were determined based on signal intensity. Proton MR spectra (STEAM; TE/TR:20/3000ms) were obtained without water suppression from a 8-ml voxel positioned in the liver during breath holding. The water signal intensity ($S_{water}$) and the methylene lipid signal $S_{meth}$ were calculated.
Differences between groups were analysed by unpaired statistical analyses (Austin, Texas, USA)). A total of 14 patients were included in each group. Caucasian. The two groups (gainers

Table 1. Patient characteristics after a mean of four years of insulin therapy

<table>
<thead>
<tr>
<th></th>
<th>Gainers</th>
<th>Non-gainers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (male/female)</td>
<td>8/6</td>
<td>10/4</td>
</tr>
<tr>
<td>Age (year)</td>
<td>63±7</td>
<td>65±7</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>9 (2-25)</td>
<td>12 (2-22)</td>
</tr>
<tr>
<td>Insulin therapy (years)</td>
<td>4.6±1.7</td>
<td>3.7±2.1*</td>
</tr>
<tr>
<td>Medication (n)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Insulin alone</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>- Insulin + Metformin</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>- Insulin + SU</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>- Insulin + Metformin + SU</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Insulin dose (U/day)</td>
<td>68±37</td>
<td>60±37</td>
</tr>
<tr>
<td>Insulin dose (U/kg)</td>
<td>0.7±0.4</td>
<td>0.7±0.4</td>
</tr>
</tbody>
</table>

Data are means±SD or median (range); *P<0.05; SU = sulfonylurea derivative.

Physical activity was measured using a SenseWear Pro Armband™ (Body Media, Pittsburgh, PA, USA). The device was placed on the right upper arm over the triceps muscle for five consecutive days. Measurements were only used for calculations if >90% of data were available. SenseWear Innerview professional software 6.1 was used to analyse the data.

Classical risk factors as blood pressure, smoking habits, lipids, renal function and albumin excretion ratio (AER) were determined. Blood pressure was measured at the right arm with the patient in a supine position after a minimum of five minutes rest. All patients had already taken their antihypertensive drugs. Blood pressure was determined twice by a manual sphygmomanometer. The average blood pressure (mean systolic and diastolic blood pressure) was calculated. Furthermore, fasting blood samples were drawn to assess: HbA1c, lipids, alanine aminotransferase (ALT), and creatinine (all determined by standard laboratory methods). Renal function expressed as glomerular filtration rate (GFR) was calculated by the modified diet in renal disease (MDRD) formula. The adipocytokines, adiponectin and leptin were determined by using DuoSet ELISA (Glastrup, Denmark), IL-6 and 18 by Luminex® (Austin, Texas, USA)).

Statistical analyses

Differences between groups were analysed by unpaired Student’s t-test and Mann-Whitney U test as appropriate. For comparing dichotomous variables the χ² test was used. All calculations were made using SPSS 16.0 for Windows (SPSS Inc., Chicago, Illinois, USA). Data are expressed as means ± SD, unless otherwise indicated. A p value <0.05 was considered significant in all statistical comparisons.

RESULTS

A total of 14 patients were included in each group. Table 1 shows the characteristics of the patients. All patients were Caucasian. The two groups (gainers vs non-gainers) were compared after a mean of 4.0±1.6 years insulin therapy (i.e. mean follow-up); as per protocol, all patients were still on biphasic insulin. Gainers were on insulin longer than non-gainers (4.6±1.7 vs 3.7±2.1 year, p=0.03).

Change in weight and HbA1c after start of insulin therapy

As per definition, gainers showed a substantially larger weight gain (+11 kg [range +5.2 to +19.6 kg]) compared with the non-gainers (+1.2 kg [range -1.6 to +2.5 kg], figure 1). Of note, body weight at the start of insulin therapy was slightly lower in gainers (83±5 kg vs 87±13 kg, p=NS). After four years of insulin therapy, BMI, waist circumference and WHR were not significantly different between the two groups (BMI 32.3±5.6 vs 29.0±4.5 kg/m², waist circumference 110±15 cm vs 106±13 cm, WHR 1.05±0.12 vs 1.03±0.10, for gainers and non-gainers, respectively, p=NS). Mean HbA1c decreased from 9.9±2.6% to 7.2±0.7% in gainers vs 8.9±1.3 to 7.4±0.9 % in non-gainers (p=NS for the difference in gainers vs the difference in non-gainers).

Cardiometabolic risk profile at follow-up

Fat distribution

Gainers had significantly more total body fat (32.4±9.4 vs 24.6±7.7 kg, p=0.03) and more trunk fat compared with non-gainers (18.3±5.5 vs 14.1±4.2 kg, p=0.04). Gainers had slightly higher TBWa compared with non-gainers (37.7±7.5 vs 35.9±4.5 litres, p=NS). FFM was comparable in gainers and non-gainers as measured by DEXA (35.4±9.1 vs 39.6±8.7 kg, p=NS) and by BIA. In both groups the trunk-to-leg ratio was similar. As measured by MRI, gainers had significantly higher subcutaneous fat than non-gainers (2.5±0.8 vs 1.8±0.8 litres, p=0.04), while visceral fat was similar (1.7±0.7 vs 1.5±0.7 litres, p=NS).

Sixteen patients (76%) had LFAT levels above the upper reference value of 5.5%. Gainers and non-gainers had similar LFAT (9.6±2.7 vs 9.3±1.6 %, respectively, p=NS).
Physical activity levels
The average total energy expenditure at follow-up was significantly lower in gainers than in non-gainers (2275±385 vs 2632±734 kcal/day, p=0.005). Physical activity duration expressed as metabolic equivalent (MET) ≥3, which is consuming ≥3 kcal/kg of body weight per hour, tended to be lower in gainers compared with non-gainers (56±51 vs 83±80 min/day, p=0.06). Also the amount of vigorous activity (MET >6) was lower in gainers than in non-gainers (2.4±3.4 vs 6.5±5.5 minutes, p=0.03). The amount of sedentary activity (MET 0-3) and moderate activity (MET 3-6) was similar between the two groups, as was the number of steps per day (5416±3543 vs 5282±3681), and the total duration of rest (514±139 vs 484±148 minutes) and sleep (409±137 vs 394±135 minutes), all gainers vs non-gainers, respectively.

Cardiometabolic markers
Prior to the start of insulin therapy the classical cardiometabolic risk markers (i.e. BMI, blood pressure, lipid profiles, smoking, GFR and AER) were similar in the two groups (table 2).

The cardiometabolic risk markers of the two groups measured in the present study are shown in table 3. Blood pressure was similar in gainers compared with non-gainers, as was the average number (2.1 vs 2.2) and dose of antihypertensive medication. Total cholesterol and low-density lipoprotein cholesterol (LDL-cholesterol) were significantly higher in gainers than in non-gainers, as was the level of high-density lipoprotein cholesterol (HDL-cholesterol), despite similar use of statins at equipotent doses.

There were no differences between the two groups with respect to smoking habits. Creatinine was slightly lower
in gainers than in non-gainers and urinary albumin excretion appeared quantitatively higher in gainers, but the differences were not significant. Calculated GFR was significantly higher in the gainers group. FFA and adiponectin levels were similar between the two groups. Leptin, and the inflammatory cytokines were slightly higher in gainers than in non-gainers. ALAT levels were significantly higher in gainers.

**DISCUSSION**

The main finding of this cross-sectional pilot study is that patients who develop pronounced weight gain after long-term insulin therapy have more total, trunk and subcutaneous fat, perform less physical activity and show slightly higher cholesterol and ALAT levels and GFR compared with those who do not gain weight. All together these findings suggest that this group of ‘gainers’ may have an unfavourable cardiometabolic risk profile compared with ‘non-gainers’.

So far, hardly any studies have investigated the effects of long-term insulin therapy on body weight as a primary endpoint. Follow-up in most studies is limited to 6 to 12 months, with a reported increase in body weight of approximately 2 to 6 kg. Whether ongoing weight increase occurs in insulin-treated patients while stable glycaemic control has been obtained is less clear. Recently, Aas et al. reported a mean weight gain approaching 4 kg over three years in insulin-treated participants of the DIGAMI study. Approximately 30% of the weight gain took place beyond one year of therapy. Also Kooy et al. found ongoing weight increase in a group of insulin-treated patients who were followed for over four years. The limited findings from literature match with general clinical experience and suggest that – at least in a subset of patients – weight continues to increase during insulin treatment without further improvement in glycaemic control. The ‘gainers’ selected in the present study may represent this group.

The two groups seemed to differ with respect to body weight before the start of insulin, with the gainers starting at a lower weight, although this difference was statistically not significant. This may suggest that gainers had lost more weight before the onset of insulin and thus simply regained more weight after starting insulin, as has been suggested before. As the initial HbA level was also slightly higher in the gainers group (not statistically significant), a relative contribution from ‘initial regain’ cannot be fully excluded. Indeed, gainers suffered a mean of 4.3 kg±6.4 kg weight loss within 12 months prior to the start of insulin therapy. However, the observed sustained increase in body weight during long-term insulin treatment cannot be attributable to exaggerated weight loss before therapy.

The adverse effect of a sustained increase in body weight during insulin treatment as found in the present study is supported by previous findings. Yki-Järvinen et al. reported higher blood pressure and lipid levels in patients with an exaggerated weight increase. In a recent report, initiation of insulin treatment after myocardial infarction

<table>
<thead>
<tr>
<th>Classical risk factors</th>
<th>Gainers</th>
<th>Non-gainers</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP (mmHg)</td>
<td>150±23</td>
<td>146±31</td>
<td>NS</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>81±10</td>
<td>80±11</td>
<td>NS</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.8±0.9</td>
<td>3.8±0.8  *</td>
<td>0.001</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>2.9±0.8</td>
<td>2.1±0.4 *</td>
<td>0.006</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>1.2±0.2</td>
<td>1.0±0.3 *</td>
<td>0.03</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>2.1±1.4</td>
<td>1.7±0.6</td>
<td>NS</td>
</tr>
<tr>
<td>Smoking (n)</td>
<td>2</td>
<td>2</td>
<td>NS</td>
</tr>
<tr>
<td>Creatinine (μmol/l)</td>
<td>85±29</td>
<td>97±38</td>
<td>NS</td>
</tr>
<tr>
<td>GFR (MDRD; ml/min/1.73 m²)</td>
<td>110±28</td>
<td>85±33 *</td>
<td>0.04</td>
</tr>
<tr>
<td>AER (μmol/min)</td>
<td>11±2±28</td>
<td>74±143</td>
<td>NS</td>
</tr>
<tr>
<td>FFA (μmol/l)</td>
<td>0.6±0.2</td>
<td>0.6±0.3</td>
<td>NS</td>
</tr>
<tr>
<td>Fat hormones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>43±26.7</td>
<td>29.7±21.3</td>
<td>NS</td>
</tr>
<tr>
<td>Adiponectin (ng/ml)</td>
<td>3.0±1.4</td>
<td>2.1±1.0</td>
<td>NS</td>
</tr>
<tr>
<td>Inflammatory markers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsCRP (pmol/ml)</td>
<td>4.8±3.3</td>
<td>3.7±4.2</td>
<td>NS</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>11.5±18.3</td>
<td>5.9±2.9</td>
<td>NS</td>
</tr>
<tr>
<td>IL-18 (pg/ml)</td>
<td>139±39</td>
<td>134±46</td>
<td>NS</td>
</tr>
<tr>
<td>Liver enzymes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALAT (U/l)</td>
<td>33±11.4</td>
<td>23.8±9.1 *</td>
<td>0.04</td>
</tr>
</tbody>
</table>

Data are means ± SD. SBP = systolic blood pressure, DBP = diastolic blood pressure, LDL = low-density lipoprotein, HDL = high-density lipoprotein, GFR = glomerular filtration rate; MDRD = modified diet in renal disease; AER = albumin excretion ratio; ALAT = alanine aminotransferase. All data were analysed by Student’s t-test, except for the data on AER, leptin, hsCRP, IL-6 and IL-18 which were analysed by nonparametric Mann-Whitney U-test. * P<0.05.
was associated with a significant increase in weight and incidence of re-infarction, although the latter was not clearly explained by the increased weight. In addition, elevated levels of adipokines were found in a group of patients treated with insulin who gained weight compared with a group treated by lifestyle intervention that lost weight, despite similar glycaemic levels. All together these data, though limited, suggest that insulin-associated weight gain may indeed negatively affect cardiometabolic risk profile.

We found that the group of subjects with pronounced weight increase had higher total, trunk and subcutaneous fat. Long-term effects of insulin-associated weight gain on body composition have not been reported, but in short-term studies, insulin treatment showed an increase in fat mass but also FFM, in line with the anabolic effect of insulin. The present study did not reveal a difference in lean body mass between the two groups. Although this does not exclude a beneficial effect of insulin treatment in itself on lean body mass, it does show that the exaggerated weight increase is explained by an increase in fat only.

Most studies suggest that visceral rather than subcutaneous fat is associated with insulin-resistance and may confer increased cardiometabolic risk. From this point of view, the currently reported increase in subcutaneous fat mass may not necessarily incur to a strongly elevated cardiometabolic risk, but may still contribute to an adverse cardiometabolic risk profile. It could be hypothesised that gainers exhibit higher levels of adipokynes (e.g. leptin, IL-6) at the level of subcutaneous adipose tissue compared with non-gainers. Furthermore, it could be argued that dietary content (e.g. ceramide intake) might influence body weight and metabolic effects on adipose tissue. Unfortunately, we did not perform subcutaneous fat biopsies in the two groups and took a standardised questionnaire survey for assessing patients dietary habits. It is known that hepatic fat accumulation is associated with (hepatic) insulin resistance in non-alcoholic fatty liver disease and is also a predictor of cardiometabolic disease. Juurinen et al. showed that after seven months of insulin therapy (basal insulin) patients had improvement of hepatic insulin sensitivity and reduction of hepatic fat content. LFAT after longer periods of insulin treatment has not been studied. The present results found no statistically significant differences between the two groups with respect to LFAT content as measured by MRS. Both groups had substantial percentages of LFAT (~10%), which is in line with results reported in literature. The number of subjects in whom LFAT measurements were successful in the study was relatively low and thus the lack of a difference may represent a power problem, especially as the slightly higher ALAT levels suggest that the group of gainers may have had slightly higher LFAT. Alternatively, higher ALAT levels may confer an elevated cardiovascular risk, independent of LFAT. MDRD-GFR was higher in the gainers, which was associated with a tendency towards lower serum creatinine and an increased albumin excretion rate. Together these results suggest the existence of glomerular hyperfiltration, which in itself has been listed as a cardiovascular risk marker. (Low-grade) inflammation and adipocytokines (i.e. leptin) are associated with obesity and cardiovascular disease. In line with this association, leptin, IL-6, IL-18 and hsCRP tended to be higher in gainers. Adiponectin levels are negatively associated with obesity and with cardiovascular endpoints. Adiponectin levels in both groups were similar, suggesting that insulin-associated weight gain does not necessarily translate in a (further) decrease in adiponectin levels.

Physical activity is a strong predictor of future cardiovascular disease and a determinant of body weight. Gainers had lower levels of total energy expenditure compared with non-gainers, and performed less vigorous exercise compared with non-gainers. Due to the cross-sectional design of our study, it cannot be determined whether the decreased level of physical exercise is the cause of the exaggerated insulin-associated weight gain or the consequence. However, no matter the cause or consequence, a low physical exercise level remains a cardiovascular risk factor. It can be speculated, for instance, that (pronounced) weight gain in insulin-treated patients and change in physical activity is associated with a decrease in mood or tendency towards depression. In this study we did not assess (changes in) mood or depression score. Further prospective work is warranted in order to investigate the relationship between insulin-associated weight gain and level of physical activity.

The study has a number of limitations. The cross-sectional comparison cannot determine whether the unfavourable cardiometabolic risk profile observed in the gainers is the direct consequence of insulin-associated weight gain. The study cannot determine whether part of the observed weight gain is due to the ‘natural’ course of body weight associated with ageing; this would require a control group of either matched non-diabetic subjects, or subjects with T2DM on oral medication. The study also has a number of strengths. There is a rather homogenous population, similarly treated patients from a single centre, all on biphasic insulin. We used a set of sophisticated techniques to quantify body fat distribution and physical activity. The results of our study may have clinical implications. As it seems that pronounced weight gain during (long-term) insulin therapy is associated with a less favourable cardiometabolic risk profile, it may be important to determine which patients are most at risk for weight gain. This would require assessment of predictive factors and
lifestyle characteristics before onset of insulin treatment, which, however, are largely unknown. Most authors view the change in glycaemic control (i.e. change in HbA1c) as the major determinant of insulin-associated weight gain. Although part of the short-term insulin-associated weight gain may be explained by change in HbA1c in this study, this cannot explain sustained weight gain after long-term insulin therapy when stable or even increased HbA1c is observed. Further prospective studies are needed to improve identification of patients who are at risk for extensive body weight increase and develop interventions to prevent the weight gain.

In conclusion, the present study suggests that pronounced weight gain during (long-term) insulin therapy in patients with T2DM is associated with an unfavourable cardiometabolic risk profile. Further work is required to determine the individual risk factors for exaggerated weight increase, to assess long-term consequences and to develop potential interventions.

ACKNOWLEDGEMENTS

We would like to thank Kristine van Doesum for the analyses of the MRI slides of each patient, and we thank Vincenzo Positano (IFC-CNR, Pisa, Italy) for kindly providing the software package HippoFat to us. We also thank Marjo van de Ven who performed the DEXA scans of each patient.

REFERENCES


